Zyban (bupropion hydrochloride)

GlaxoSmithKline

Section: 20(b) Poisoning, Toxicity and Drug Dependence - Agents used in drug dependence Permitted in sport

Zyban (Modified Release Tablets)

  • This product may cause drowsiness
  • Bupropion HCl
  • Prescription only
  • Pack: 150 mg [30] Subsidy: not subsidised Manufacturer Price: $65.80 Patient Charge: $113.51
  • Dose: May be taken with or without food.
  • Adults: initially 150 mg daily for 3 days, then 150 mg twice daily (allow min. 8 hours between doses). Max. 150 mg/dose and 300 mg/day.
  • Hepatic, renal impairment: see full PI.

Uses: Selective noradrenaline and dopamine reuptake inhibitor. Treatment of depression. Also for nicotine dependence as an aid to smoking cessation.

Contraindications: Seizure disorders (or history); CNS tumour; abrupt alcohol or sedative withdrawal; bulimia, anorexia nervosa (or history); MAOls (discontinue at least 14 days before starting Zyban); concomitant bupropion containing preparations.

Precautions: History of head trauma; concomitant medications lowering seizure threshold, e.g. antipsychotics, antidepressants, antimalarials, tramadol, theophylline, systemic steroids, quinolones. sedating antihistamines: excessive alcohol, sedative use; diabetes treated with hypoglycaemics or insulin; use of stimulants, anorectics; hepatic, renal impairment; hepatic cirrhosis; history of psychiatric illness esp bipolar disorder; concomitant transdermal nicotine; elderly; pregnancy, lactation, children < 18 years.

Adverse reactions: Fever; chest pain; asthenia; tachycardia; vasodilatation; postural hypotension; increased BP; flushing; syncope; seizures; insomnia; tremor; dystonia; ataxia; parkinsonism; twitching; incoordination; concentration disturbance; headache; dizziness; depression; confusion; hallucinations; agitation; anxiety; irritability; hostility; depersonalisation; abnormal dreams; memory impairment; paraesthesia; anorexia; blood glucose disturbances; dry mouth; GI upset; urinary frequency and/or retention; hepatotoxicity; rash; pruritus; sweating; hypersensitivity reactions; bronchospasm; arthralgia, myalgia; tinnitus; visual disturbance; taste disorder.

Rare: anaphylactic shock; erythema multiforme; Stevens-Johnson syndrome.

Interactions: CYP4::S0 ~ Drugs which lower seizure threshold (see Precautions); drugs affecting CYP2B6 incl orphenadrine. cyclophosphamide, ifosfamide; drugs metabolised by CYP2D6, e.g. antidepressants (desipramine, imipramine. paroxetine), antipsychotics (risperidone, thioridazine), l3-blockers (metoprolol), type 1 C antiarrhythmics (propafenone, flecainide); carbamazepine; phenobarbitone; phenytoin; levodopa; amantadine.

Patient Information: May impair concentration. Take care if driving a vehicle or operating machinery until effects are known. Minimise or avoid alcohol consumption during treatment. Swallow tablets whole, do not crush or chew.

Local consumer information here and for professionals here